Key clinical and biomarker characteristics of patients with distinct COO subtypes: GCB, unclassified, and ABC DLBCL
| Characteristic . | GCB (n = 540) . | Unclassified (n = 150) . | ABC (n = 243) . |
|---|---|---|---|
| Age, median (range), y | 62.5 (18-83) | 62.0 (21-83) | 64.0 (29-86) |
| <60 | 228 (42.2) | 59 (39.3) | 70 (28.8) |
| ≥60 | 312 (57.8) | 91 (60.7) | 173 (71.2) |
| ECOG PS | |||
| 0-1 | 475 (88.1) | 126 (84.0) | 209 (86.0) |
| 2-3 | 64 (11.9) | 24 (16.0) | 34 (14.0) |
| Ann Arbor stage | |||
| I or II | 146 (27.0) | 34 (22.7) | 52 (21.4) |
| III or IV | 394 (73.0) | 116 (77.3) | 191 (78.6) |
| Elevated LDH | 308 (57.1) | 76 (50.7) | 169 (70.4) |
| Extranodal sites, n | |||
| 0-1 | 355 (65.7) | 95 (63.3) | 158 (65.0) |
| >1 | 185 (34.3) | 55 (36.7) | 85 (35.0) |
| Involvement of kidneys and/or adrenal glands | 36 (6.7) | 9 (6.0) | 13 (5.3) |
| CNS-IPI | |||
| Low (0-1) | 115 (21.3) | 29 (19.3) | 28 (11.5) |
| Intermediate (2-3) | 335 (62.0) | 97 (64.7) | 164 (67.5) |
| High (4-6) | 90 (16.7) | 24 (16.0) | 51 (21.0) |
| BCL2/MYC dual expression | n = 381 | n = 114 | n = 193 |
| Nodual expressers | 264 (69.3) | 72 (63.2) | 57 (29.5) |
| Dual expressers | 117 (30.7) | 42 (36.8) | 136 (70.5) |
| Characteristic . | GCB (n = 540) . | Unclassified (n = 150) . | ABC (n = 243) . |
|---|---|---|---|
| Age, median (range), y | 62.5 (18-83) | 62.0 (21-83) | 64.0 (29-86) |
| <60 | 228 (42.2) | 59 (39.3) | 70 (28.8) |
| ≥60 | 312 (57.8) | 91 (60.7) | 173 (71.2) |
| ECOG PS | |||
| 0-1 | 475 (88.1) | 126 (84.0) | 209 (86.0) |
| 2-3 | 64 (11.9) | 24 (16.0) | 34 (14.0) |
| Ann Arbor stage | |||
| I or II | 146 (27.0) | 34 (22.7) | 52 (21.4) |
| III or IV | 394 (73.0) | 116 (77.3) | 191 (78.6) |
| Elevated LDH | 308 (57.1) | 76 (50.7) | 169 (70.4) |
| Extranodal sites, n | |||
| 0-1 | 355 (65.7) | 95 (63.3) | 158 (65.0) |
| >1 | 185 (34.3) | 55 (36.7) | 85 (35.0) |
| Involvement of kidneys and/or adrenal glands | 36 (6.7) | 9 (6.0) | 13 (5.3) |
| CNS-IPI | |||
| Low (0-1) | 115 (21.3) | 29 (19.3) | 28 (11.5) |
| Intermediate (2-3) | 335 (62.0) | 97 (64.7) | 164 (67.5) |
| High (4-6) | 90 (16.7) | 24 (16.0) | 51 (21.0) |
| BCL2/MYC dual expression | n = 381 | n = 114 | n = 193 |
| Nodual expressers | 264 (69.3) | 72 (63.2) | 57 (29.5) |
| Dual expressers | 117 (30.7) | 42 (36.8) | 136 (70.5) |
Data are presented as n (%), unless otherwise noted. Data for ECOG PS were not available in 1 case, and data on LDH were not available in 3 cases.